Maternus-Kliniken Aktiengesellschaft risk profile
44 Elevated one input has moved against it
Measured 1 September 2026 from MAK's filed statements. Recomputed nightly.
44 (Elevated), driven by Market expectation at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 100 | Acute | Volatile | One-year price volatility — 363.7% |
| Operating pressure | 38 | Normal | Worsening | Costs outgrowing revenue — +1.7 percentage points |
| Cash conversion | 28 | Normal | Worsening | Capital spending against operating cash — 0.20x |
| Leverage and coverage | 98 | Acute | Worsening | Net debt to EBITDA — 44.01x |
| Competitive position | 22 | Normal | Stable | Revenue-growth gap against peers — +0.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Maternus-Kliniken Aktiengesellschaft